Revelation Biosciences In... (REVB)

NasdaqCM: REVB · Real-Time Price · USD

1.07

-0.04 (-3.60%)

At close: Aug 21, 2026, 8:00 PM

1.07

-1.83%

After-hours: 7:39 PM

The price, the headline numbers and the latest news, in one place.

-3.60% (1D)

No data available

Bid	0.8
Market Cap	4.34M
Revenue (ttm)	n/a
Net Income (ttm)	-19.2M
	-0.17
	27.03
	0.04
	-0.38
P/B (ttm)	0.42
P/S (ttm)	n/a
Earnings Date	Nov 5, 2026

Ask	1.39
Volume	14,545
Avg. Volume (20D)	43,260
Open	1.12
Previous Close	1.11
Day's Range	1.07 - 1.14
52-Week Range	0.88 - 11.72
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About REVB

Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 17, 2020

Employees 8

Stock Exchange NasdaqCM

Ticker Symbol REVB

Website https://www.revbiosciences.com

Full Company Profile

Financial Performance

In 2025, Revelation Biosciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -8.91M, a decrease of -40.73%.

Financial Statements